Bio & Pharma
S. Korea's SillaJen launches clinical trials in US for new anti-cancer drug
The biotech company will adopt a candidate substance from a Swiss pharmaceutical company
By Dec 14, 2022 (Gmt+09:00)
1
Min read
Most Read
S.Korea's LS Materials set to boost earnings ahead of IPO process
![close](/images/ico/eyes/close.png)
![open](/images/ico/eyes/open.png)
Macquarie eyes its 1st Korean data center valued around $722 mn
![close](/images/ico/eyes/close.png)
![open](/images/ico/eyes/open.png)
Galaxy Ring, new foldables set to steal the show at Samsung Unpacked Paris
![close](/images/ico/eyes/close.png)
![open](/images/ico/eyes/open.png)
SK Inc. in talks to sell Pharmteco’s US CDMO plant to Novo Nordisk
![close](/images/ico/eyes/close.png)
![open](/images/ico/eyes/open.png)
POSCO gears up for carbon-free steelmaking with hydrogen
![close](/images/ico/eyes/close.png)
![open](/images/ico/eyes/open.png)
![Kim Jae-kyung, CEO of Korean biotech company SillaJen](https://www.kedglobal.com/data/ked/image/2022/12/14/ked202212140003.700x.0.jpg)
South Korean biotech company Sillajen Inc. has started recruiting patients for Phase 1 clinical trials in the US for an anti-cancer drug from a Swiss pharmaceutical company.
SillaJen plans to expedite clinical development and promote technology transfer.
SillaJen CEO Kim Jae-kyung on Tuesday told a news conference at Korea Press Center in Seoul, "Three clinical institutions in the US this month will start recruiting patients for Phase 1 clinical trials of BAL0891," adding, "We will quickly conduct Phase 1 to fill the unmet demand for new anti-cancer drugs."
The company plans to hold clinical trials for intractable carcinomas such as those of triple-negative breast cancer and expand indications to other carcinomas such as those of blood cancer. BAL0891, a candidate substance for suppressing mitotic checkpoints, was introduced by SillaJen from Basilia Pharmaceutica International of Switzerland; the Korean company also has an exclusive license for use of the substance.
Preclinical studies have shown that BAL0891 effectively inhibits an array of cancer cells including those of triple-negative breast, endometrial, colorectal, urothelial, gastric and kidney cancer. Intravenous administration of the drug instead of oral also proved more effective against cancer.
Write to Jae-Young Han at jyhan@hankyung.com
More to Read
Comment 0
LOG IN